According to the article, that investor aims to influence the company's choice of a chief executive.

The current health news highlights a series of dynamic events, including Parvus Asset Management's stake in Novo Nordisk, WHO ...

Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk, after the company lost its first mover ...

In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin ...

CVS Caremark identified GLP-1 drugs and Humira as points of contention, but the State Health Plan says that mischaracterizes ...

The European Medicines Agency has indicated that Novo Nordisk's drugs, Ozempic and Wegovy, may rarely cause a serious eye ...

Many companies have failed to disrupt the complicated U.S. healthcare market. Hims & Hers (NYSE: HIMS) may finally be ...

Novo Nordisk Thailand has signed an MoU with HSRI – and the Health Systems Research Institute  – to strengthen Thailand’s clinical research infrastructure and foster healthcare innovation. The ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Health-care companies rose as investors bet on anti-obesity products. Omada Health shares jumped after the maker of digital products that help track diet and other diabetes factors made its ...

After reviewing several large epidemiological studies, clinical trial and in-market data, EMA’s Pharmacovigilance Risk Assessment Committee has concluded non-anterior ischemic optic neuropathy is a ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.